EyeWorld India December 2018 Issue

24 EWAP FEATURE September 2017 between the two, each technology has particular advantages. The femtosecond laser can soften and fragment the nucleus and make incisions, which Zepto cannot do. But Zepto fits more easily into the flow of surgery, can be used with small pupils, is more affordable, and does not put any extra energy into the eye. “Instead of using capsulorhexis forceps, they hand me the Zepto device, I insert it, do the capsulot- omy, then move on, and it doesn’t add any time or inconveniences in terms of the efficiency of our OR flow,” Dr. Swan said. Zepto is intended to be more of a mass-market device than the femtosecond laser, according to Dr. Sretavan. “We wanted to make sure that not only the highly skilled sur- geons could use it, but the aver- age surgeon could use it,” he said. “There are great surgeons out there who can do a manual [capsu- lorhexis] very well by hand, and they do it fast, but not everyone is like that. “For a lot of surgeons, a Zepto capsulotomy is quicker, it’s more consistent, they get the size that they want, and the sizing comes with the benefits of a ‘perfect’ cap- sulotomy that the field has known about for a long time.” One of the unique features of the technology is that it’s flexible; there’s a low barrier to entry, Dr. Sretavan continued. “You don’t have to commit half a million dol- lars and a whole room and hire a new technician to adopt the tech- nology.” EWAP Editors’ note: Dr. Sretavan and Dr. Waltz have financial interests with Mynosys Cellular Devices. Dr. Kretz has financial interests with Vision Ophthalmology Group (Frankfurt, Germany). Dr. Swan has no financial interests related to his comments. Contact information Kretz: f.kretz@augenklinik.de Sretavan: sretavan@mynosys.com Swan: russell.swan@vancethompsonvision. com Waltz: kwaltz56@gmail.com Zepto: More – from page 23 D ce er 2018